Compare Abeona Therapeutics Inc (ABEO) vs Canopy Growth Corp (CGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Canopy Growth Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Canopy Growth Corp trades at $0.96 (market cap $404.40M). The key difference: Abeona Therapeutics Inc and Canopy Growth Corp are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | CGC | |
|---|---|---|
Market Cap | $373.32M | $404.40M |
Sector | Health | Health |
52-Week High | $7.23 | $1.92 |
52-Week Low | $4.17 | $0.86 |
Enterprise Value | $228.22M | $343.85M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CGC trades at $0.95, down 5% on the day, with a bearish technical signal and negative earnings momentum after recent quarterly misses. The company reported a net loss of $598.12 million in 2025, with a net income margin of -222.36%, though revenue trends show some stabilization. Cash flow remains negative, and the stock faces Nasdaq listing compliance risks due to its low price, with news highlighting potential for a reverse stock split.
The outlook is highly speculative with significant operational and financial risks. While valuation ratios like P/S of 1.44 and P/B of 0.83 appear modest, persistent losses and high debt levels overshadow any near-term upside. Investor sentiment is mixed among analysts, with a slight hold bias, but the path to profitability remains uncertain amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
